CFDE Data Portal | Search AATBC

	Label	Description
	AATBC Gene (Entity type)	ENSG00000215458 - apoptosis associated transcript in bladder cancer
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS

AATBC

ENSG00000215458 - apoptosis associated transcript in bladder cancer

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human up

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

GSE216043 cisplatin 11 v 4 human dn

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.